# Illumina Inc. (ILMN) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $218.22, market value $33.0 billion.

## Valuation
- **P/E (trailing): 40.6×** (5-yr avg 49.1×, 3-yr avg 24.8×). Illumina Inc. trades at 40.6× trailing earnings, close to its own five-year average of 49.1×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 35.8×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.21**. A PEG of 0.21 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 7.3×**. Each dollar of revenue is priced at 7.3×.
- **Price / book: 11.6×**. The shares trade at 11.6× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: 2.8%** (5-yr avg 2.0%). Free cash flow equals 2.8% of the market value, above its five-year average of 2.0%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 2.5%**. The inverse of the P/E: 2.5% of the price is earned each year.

## Profitability
- **Gross margin: 66.4%**. Illumina Inc. keeps 66.4% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 19.7%**. 19.7% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 19.6%**. 19.6% of each dollar of sales reaches the bottom line.
- **Return on equity: 31.2%**. 31.2% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 20.5%**. Return on all capital, debt included, is 20.5%: comfortably above what that capital costs.
- **Return on assets: 12.4%**. Each dollar of assets produces 12.4% of profit.

## Growth
- **Revenue growth (1 yr): -0.7%** (3-yr -1.8%/yr, 5-yr 6.0%/yr). Revenue fell 0.7% over the last year, against 6.0% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 170.9%** (5-yr 4.1%/yr). Earnings per share rose 170.9%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 106.3%/yr**. Free cash flow has compounded at 106.3% a year over three years.

## Financial health
- **Debt to equity: 0.25**. Debt is 0.25 times equity: a conservative balance sheet.
- **Current ratio: 2.08** (quick 2.08). Current assets cover the next year's liabilities 2.08 times.
- **Piotroski F-score: 8/9**. 8 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend: none**. Illumina Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (19 analysts). 19 analysts cover Illumina Inc.; the consensus is buy, with an average price target of $199.63 (-9% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 123.4%** (YTD 66.4%, 3-mo 34.4%). The shares are up 123.4% over twelve months including dividends.
- **From 52-week high: -5.9%** (148.0% above the low). Trading 6% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 59**. An RSI of 59 is neutral.
- **Beta (1 yr): 0.83** (volatility 48%). Beta of 0.83 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ILMN · Page: https://foliofundamentals.com/stocks/ilmn

Not investment advice.